Current and historical daily PS Ratio for AbbVie Inc (
) from 2012 to Jul 21 2026. The price to sales ratio is calculated by taking the current stock price and dividing it by the trailing twelve-month sales per share. The data is updated every 20 minutes during market hours. The PS ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS ratio is a great valuation tool for evaluating cyclical businesses where the PE ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean. AbbVie stock (ABBV) PS ratio as of Jul 21 2026 is 7.2.
More Details
AbbVie Inc (ABBV) PS Ratio Chart
AbbVie Inc (ABBV) PS Ratio Historical Data
View and export this data going back to 2012. Start your Free Trial
Total 1207
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| AbbVie PS Ratio Historical Data | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date | PS Ratio Data | Date | PS Ratio Data | ||||||
| 2026-07-21 | 7.2 | 7.26 | 7.13 | 7.2 | 2026-05-14 | 5.9 | 6.03 | 5.88 | 5.95 |
| 2026-07-20 | 7.1 | 7.23 | 7.13 | 7.15 | 2026-05-13 | 5.8 | 5.91 | 5.77 | 5.88 |
| 2026-07-17 | 7.3 | 7.37 | 7.18 | 7.18 | 2026-05-12 | 5.8 | 5.96 | 5.74 | 5.87 |
| 2026-07-16 | 6.9 | 7.18 | 6.87 | 7.18 | 2026-05-11 | 5.7 | 5.8 | 5.7 | 5.72 |
| 2026-07-15 | 6.9 | 6.99 | 6.86 | 6.89 | 2026-05-08 | 5.7 | 5.71 | 5.65 | 5.69 |
| 2026-07-14 | 6.9 | 6.96 | 6.86 | 6.91 | 2026-05-07 | 5.8 | 5.84 | 5.7 | 5.72 |
| 2026-07-13 | 7.0 | 7.05 | 6.9 | 7 | 2026-05-06 | 5.8 | 5.84 | 5.75 | 5.79 |
| 2026-07-10 | 7.1 | 7.1 | 6.92 | 7 | 2026-05-05 | 5.9 | 5.91 | 5.81 | 5.82 |
| 2026-07-09 | 7.1 | 7.19 | 7 | 7.05 | 2026-05-04 | 5.8 | 5.88 | 5.78 | 5.88 |
| 2026-07-08 | 7.2 | 7.22 | 7.08 | 7.13 | 2026-05-01 | 6.0 | 5.96 | 5.8 | 5.83 |
| 2026-07-07 | 7.3 | 7.35 | 7.18 | 7.19 | 2026-04-30 | 5.9 | 6.06 | 5.88 | 5.96 |
| 2026-07-06 | 7.3 | 7.36 | 7.16 | 7.19 | 2026-04-29 | 5.4 | 5.81 | 5.38 | 5.75 |
| 2026-07-02 | 7.1 | 7.38 | 7.07 | 7.37 | 2026-04-28 | 5.6 | 5.62 | 5.54 | 5.58 |
| 2026-07-01 | 7.1 | 7.11 | 6.99 | 7.09 | 2026-04-27 | 5.6 | 5.69 | 5.54 | 5.57 |
| 2026-06-30 | 7.2 | 7.21 | 7.06 | 7.1 | 2026-04-24 | 5.6 | 5.65 | 5.56 | 5.61 |
| 2026-06-29 | 7.1 | 7.23 | 7.03 | 7.18 | 2026-04-23 | 5.7 | 5.72 | 5.66 | 5.67 |
| 2026-06-26 | 6.9 | 7.15 | 6.91 | 7.15 | 2026-04-22 | 5.8 | 5.81 | 5.64 | 5.66 |
| 2026-06-25 | 6.6 | 6.9 | 6.59 | 6.86 | 2026-04-21 | 5.8 | 5.82 | 5.67 | 5.79 |
| 2026-06-24 | 6.7 | 6.7 | 6.57 | 6.63 | 2026-04-20 | 5.9 | 5.88 | 5.73 | 5.75 |
| 2026-06-23 | 6.6 | 6.64 | 6.53 | 6.63 | 2026-04-17 | 5.9 | 5.99 | 5.87 | 5.88 |
| 2026-06-22 | 6.3 | 6.56 | 6.26 | 6.49 | 2026-04-16 | 5.9 | 5.92 | 5.83 | 5.9 |
| 2026-06-18 | 6.3 | 6.28 | 6.08 | 6.11 | 2026-04-15 | 5.9 | 5.92 | 5.8 | 5.88 |
| 2026-06-17 | 6.3 | 6.29 | 6.18 | 6.24 | 2026-04-14 | 5.8 | 5.94 | 5.76 | 5.93 |
| 2026-06-16 | 6.3 | 6.31 | 6.19 | 6.28 | 2026-04-13 | 5.8 | 5.87 | 5.73 | 5.83 |
| 2026-06-15 | 6.4 | 6.39 | 6.21 | 6.25 | 2026-04-10 | 6.0 | 6.04 | 5.86 | 5.87 |
| 2026-06-12 | 6.4 | 6.45 | 6.33 | 6.43 | 2026-04-09 | 5.9 | 6.03 | 5.89 | 5.99 |
| 2026-06-11 | 6.4 | 6.42 | 6.32 | 6.34 | 2026-04-08 | 5.8 | 5.99 | 5.77 | 5.97 |
| 2026-06-10 | 6.4 | 6.41 | 6.33 | 6.35 | 2026-04-07 | 5.8 | 5.83 | 5.69 | 5.82 |
| 2026-06-09 | 6.3 | 6.41 | 6.26 | 6.36 | 2026-04-06 | 5.8 | 5.9 | 5.79 | 5.83 |
| 2026-06-08 | 6.4 | 6.45 | 6.24 | 6.3 | 2026-04-02 | 6.0 | 6.06 | 5.86 | 5.89 |
| 2026-06-05 | 6.4 | 6.5 | 6.38 | 6.41 | 2026-04-01 | 6.2 | 6.22 | 6.03 | 6.07 |
| 2026-06-04 | 6.3 | 6.35 | 6.2 | 6.35 | 2026-03-31 | 6.1 | 6.19 | 6.06 | 6.14 |
| 2026-06-03 | 6.1 | 6.2 | 6.03 | 6.13 | 2026-03-30 | 6.0 | 6.04 | 5.95 | 6.02 |
| 2026-06-02 | 6.0 | 6.11 | 5.9 | 6.08 | 2026-03-27 | 6.1 | 6.19 | 6.06 | 6.07 |
| 2026-06-01 | 6.1 | 6.11 | 5.97 | 6.01 | 2026-03-26 | 6.0 | 6.13 | 5.96 | 6.12 |
| 2026-05-29 | 6.2 | 6.2 | 6.07 | 6.15 | 2026-03-25 | 6.0 | 6.08 | 5.97 | 6.01 |
| 2026-05-28 | 6.1 | 6.19 | 6.09 | 6.17 | 2026-03-24 | 5.9 | 5.97 | 5.85 | 5.95 |
| 2026-05-27 | 6.0 | 6.09 | 5.97 | 6.08 | 2026-03-23 | 6.0 | 6.05 | 5.89 | 5.94 |
| 2026-05-26 | 6.1 | 6.13 | 5.98 | 6.02 | 2026-03-20 | 6.0 | 6.02 | 5.89 | 5.94 |
| 2026-05-22 | 6.1 | 6.21 | 6.09 | 6.09 | 2026-03-19 | 6.0 | 6.1 | 5.92 | 5.98 |
| 2026-05-21 | 6.0 | 6.09 | 5.91 | 6.05 | 2026-03-18 | 6.3 | 6.35 | 6.02 | 6.04 |
| 2026-05-20 | 6.0 | 6.05 | 5.97 | 5.99 | 2026-03-17 | 6.4 | 6.47 | 6.37 | 6.37 |
| 2026-05-19 | 5.9 | 6.09 | 5.89 | 6.03 | 2026-03-16 | 6.4 | 6.5 | 6.39 | 6.42 |
| 2026-05-18 | 5.9 | 5.97 | 5.86 | 5.91 | 2026-03-13 | 6.5 | 6.63 | 6.36 | 6.37 |
| 2026-05-15 | 6.0 | 6.07 | 5.9 | 5.94 | 2026-03-12 | 6.5 | 6.6 | 6.48 | 6.53 |
AbbVie Inc (ABBV) PS Ratio Comparison
| Company | Market Cap(Mil) | PS Ratio |
|---|
Business Description
Business Description
AbbVie Inc
NAICS : 325412
SIC : 5122
ISIN : US00287Y1091
Share Class Description:
ABBV: Ordinary SharesTotal Employee Number:
57,000Compare
Compare
Traded in other countries / regions
ABBV.USA0QCV.UKABBV.CanadaABBV.ArgentinaABBV34.Brazil4AB.GermanyABBV.Mexico1ABBV.ItalyABBV.AustriaABBV.SwitzerlandABBVCL.Chile4AB.Bulgaria Index Membership
S&P 500Russell 1000Russell 3000Dividend KingMSCI World Index IPO Date
2012-12-10Description
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers